26.06.2012 • News

Siegfried Appoints René Imwinkelried Head of R&D

The Board of Directors of Siegfried Holding appointed René Imwinkelried, Ph.D., the company's new Head Research & Development and member of the Executive Committee. He is currently Head of Technical Development Small Molecules at Roche in Basel. René Imwinkelried will start in his new function on September 1st, 2012.

He succeeds Wolfgang Wienand, Ph.D., who held this position since August 2010 and will now focus on further developing Strategy and Mergers & Acquisitions in the Executive Committee and on his responsibility for Legal and IP Management. Wolfgang Wienand will continue to execute both functions until René Imwinkelried joins Siegfried.

For personal reasons, Beat In-Albon, Ph.D., has with immediate effect resigned from the Board of Directors of Siegfried Holding.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

most read